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Lung Cancer in HIV-Positive Patients
Suchita Pakkala, MD, and Suresh S. Ramalingam, MD
Abstract: Malignancies account for more than a third of all deaths
in human immunodeficiency virus (HIV)-positive patients. Al-
though acquired immunodeficiency syndrome-related mortality is
decreasing with the introduction of effective antiretroviral therapy,
the incidence of lung cancer in patients with HIV remains high.
Lung cancer has now become the leading cause of mortality among
the nonacquired immunodeficiency syndrome defining malignan-
cies. Within the HIV population, the incidence of lung cancer is
estimated to be approximately 2 to 4 times that of the general
population. Often these patients present with advanced disease
(stage III or IV) at a younger age and have an inferior overall
survival, when compared with non-HIV patients. Development of
lung cancer in patients with HIV has been linked to various factors
including immunosuppression, CD4 count, viral load, and smoking.
This article reviews the impact of HIV on the incidence, risk factors,
clinical presentation, and treatment of lung cancer.
Key Words: Lung cancer, HIV, AIDS, Antiretroviral therapy,
NSCLC.
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The acquired immunodeficiency syndrome (AIDS) epi-demic began in 1981 with reports of previously healthy
males developing diseases that had otherwise been limited to
immunocompromised patients. Among the diseases reported,
certain cancers, specifically Kaposi sarcoma (KS) quickly
emerged as having an association with the newly described
acquired immunodeficiency syndrome.1 Since those early
days, similar associations have been seen with non-Hodgkin
lymphoma and cervical cancer. According to current Centers
for Disease Control (CDC) guidelines, these three cancers are
now described as AIDS defining cancers (ADCs).2 In 1996,
with the introduction of highly active antiretroviral therapy
(HAART), the incidence of KS and non-Hodgkin lymphoma
decreased significantly mirroring the decrease seen in AIDS-
related morbidity and mortality.3–12
In the pre-HAART era, the non-AIDS defining cancers
(NADCs) such as lung cancer only accounted for an esti-
mated 10 to 20% of all cancers in the human immunodefi-
ciency virus (HIV) population. Nevertheless, as AIDS-related
illnesses declined, the proportion of NADCs has more than
doubled in the post-HAART era.5–7,13 A recent study dem-
onstrated a significant increase in the proportion of NADC
from 20% in the pre-HAART era to 71% of all cancers in the
modern era (2001–2006).6
Together, ADCs and NADCs account for up to a third
of all deaths in HIV-positive patients.14 The shift in incidence
that accompanied the use of HAART has also impacted
mortality, making NADCs one of the leading causes of death
with lung cancer being the most fatal.14–20
Although lung cancer is the most common and deadliest
cancer worldwide,21 it disproportionately affects HIV-positive
patients resulting in a higher incidence and a worse prognosis,
when compared with the general population.7–10,22–48
INCIDENCE
Early in the AIDS epidemic, several case reports noted the
occurrence of lung cancer in HIV-positive patients younger than
40 years.49,50 This raised the question of whether HIV-infected
patients are at a higher risk for developing lung cancer. Many
studies have compared the incidence of lung cancer cases in
patients with HIV to the general population by calculating age-
and sex-adjusted standardized incidence ratios (SIRs). SIR is an
estimate of the ratio of the incidence of cancer in a given patient
subset compared with the projected cancer incidence in the
population at large. For instance, an SIR of 1 would indicate
that lung cancer occurs more frequently in HIV-infected patients
than in the general population. Some studies have used incidence
rates to describe the number of new cases per persons at risk
within a given time.
Pre-HAART Era
Studies in the pre-HAART era demonstrated a wide
variability in lung cancer incidence with SIRs as high as 6.5
(confidence interval [CI]: 4.5–8.9),34,39 whereas others failed
to demonstrate any elevations at all51–53 (Table 1). Many of
these studies are limited by small patient numbers, especially
in an era when AIDS-related illnesses predominated over
non-AIDS-related illnesses. The largest study to examine this
issue comprised 302,834 patients with AIDS in 11 US re-
gions from 1978 to 1996. It demonstrated that lung cancer
(n  808) was the most commonly diagnosed NADC with a
SIR of 4.5 (95% CI: 4.2–4.8).36 Further analysis of this
Match registry also showed that lung cancer incidence rose as
the AIDS epidemic progressed (SIR of 2.5 [95% CI: 1.9–3.3]
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in 1980–1989 versus 3.3 [95% CI: 2.9–3.8] in
1990–1995).7,54 Other large US studies substantiated the
findings of the Match database with lung cancer SIRs of 3.3
(95% CI: 2.8–3.9) (1981–1994) and 3.5 (95% CI: 2.9–3.8)
(1992–1995) among HIV-infected people.9,44 In contrast to
larger US studies, most European studies demonstrated SIRs
that did not exceed 1.13 before HAART,30,35,47 although this
finding was not consistent across Europe.32,38
Post-HAART Trends
Despite the use of antiretroviral (ARV) therapy, HIV-
infected patients remain at higher risk for developing lung
cancer than their non-HIV counterparts as evident by SIRs
that range from 2 to 6 (Table 1).7–9,28,30,35,37,38 Patel et al.
investigated lung cancer trends in 54,780 patients with HIV
from 1992 to 2003 by examining the incidence rates and SIRs
of two large US multicenter prospective cohorts: Adult and
Adolescent Spectrum of HIV Disease (ASD) and HIV Out-
patient Study (HOPS). During this period, a total of 140
patients developed lung cancer with an incidence rate that
peaked in 1996 and a SIR of 3.3 (95% CI: 2.8–3.9).9 Overall,
there was a nonsignificant upward trend in the incidence rate
that was also described in other separate single institution
TABLE 1. Lung Cancer Incidence
Study Location Period
Lung Cancer/
HIV Population
Overall
SIR (CI)
Pre-HAART HAART
Late
Post-HAART
SIR (yr) CI SIR (yr) CI SIR (yr) CI
Koblin
et al.52
US: NY, SF 1978–1990 20/15,565 0.6 0.4–2.8
Grulich
et al.34
Australia 1980–1993 6/3616 3.8 1.39–8.29
Gallagher
et al.44
US: NY 1981–1994 217/122,993 3.3 2.86–3.75
Cooksley
et al.53
US: Texas 1974–1994 18/14,986 0.6 0.03–1
Frisch
et al.36
US: 11 areas 1978–1996 808/302,834 4.5 4.2–4.8
Parker
et al.39
US: Texas 1990–1995 36/26,181 6.5 4.5–8.9
Grulich
et al.31
Australia 1985–1999 17/13,067 1.4 (0.84–2.30)
Herida
et al.30
France 1992–1999 99/77,025 1.13 0.71–1.72 2.12 1.67–2.65
Hessol
et al.57
US: SF 1990–2000 86/14,210 2.6 (2.1–3.2)
Bower
et al.47
England 1986–2001 11/8400 0.8/10,000 0.2–3.2 6.7/10,000 3.1–13.9
Engels
et al.7
US: 11 areas 1980–2002 393/375,933 2.5 (80–89) 1.9–3.3 2.6 2.1–3.1
3.3 (90–95) 2.9–3.8
Engels
et al.37a
US: Hopkins 1989–2003 33/5238 4.7 (3.2–6.5) 1.7 0.2–6.3 5.2 (95–99) 2.8–8.7 5.3 (00–03) 3.1–8.4
Clifford
et al.10
Switzerland 1985–2003 14/7304 3.2 (1.7–5.4)
Dal Maso
et al.32
Italy 1986–2004 54/21,951 2.1 1.2–3.3 4.1 (97–04) 2.9–5.5
Patel
et al.9
US: 13 areas 1992–2003 140/54,780 3.3 (2.8–3.9) 3.5 2.5–4.9 3.8 (96–99) 2.8–5 3.6 (00–03) 2.8–4.6
Powles
et al.35
Europe 1983–2007 18/11,112 1.95 (1.16–3.1) 0 0–1.52 3.1 (96–01) 1.34–6.11 2.37 (02–07) 1.14–4.36
Bedimo
et al.28
US: VA
System
1997–2004 504/33,420 2b 1.8–2.2
Long
et al.8a
US: Hopkins 1996–2005 29/2566 5.5 3.7–8
Guiguet
et al.27
France 1998–2006 207/52,278 1.73 0.85/1000 0.74–0.97
Silverberg
et al.45b
US: Kaiser 1996–2007 54/20,227 1.9 (1.4–2.5) 3.9 (96–99) 2.1–7.1 1.1 (00–03) 0.6–1.9
2.1 (04–07) 1.4–3.2
a Compared with Urban population.
b Compared with HIV negative cohort.
US, the United States; HIV, human immunodeficiency virus; SIR, standardized incidence ratio; CI, confidence interval; HAART, highly active antiretroviral therapy; VA,
Veteran’s Administration.
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studies.8,37 Although crude incidence rates seem to be in-
creasing with HAART, an Italian study noted that rates are
tempered when adjusted for age.55 In contrast, lung cancer
incidence has significantly declined in the general population
over this time period.9 Hence, when comparing the incidence
in HIV-infected patients to the general population, Patel et
al.9 noted no consistent trends except that the standardized
rate ratio peaked at 3.8 with early HAART use. Therefore,
since HAART, crude incidence rates for lung cancer appear
to be rising likely as a consequence of an increasing HIV
prevalence and an aging population. Nevertheless, there is
some evidence to suggest that the use of HAART is accom-
panied by a decrease in SIRs.
The Match database demonstrated a similar SIR pattern
from 1992 to 2002, but the peak in incidence occurred earlier
in 1994.7 This slightly earlier peak in incidence may be
explained by the fact that the Match registry is an AIDS
registry, and the incidence of AIDS peaked around 1993 after
the CDC broadened the definition.2 Furthermore, unlike in
the pre-HAART era, these trends do not seem to be limited
to the United States. In a European study of 11,112 HIV-
positive patients, the SIR peaked at 3.1 in 1996–2001 but
subsequently fell to 2.27 in 2002–2007.35 Extended follow-up
in the post-HAART era has shown that although lung cancer
rates have declined, the incidence remains elevated.
Impact of ARV Therapy
A meta-analysis of 847 lung cancer cases illustrated
that the availability of HAART did not significantly alter lung
cancer incidence which remained elevated.33 Another study
examined 96,000 HIV-positive patients in 19 North Ameri-
can cohorts from 1988 to 2007 and found that lung cancer
incidence has not changed.56 Nevertheless, most studies have
examined the effect of periods (e.g., pre-HAART and post-
HAART) on the incidence of NADCs rather than the actual
impact of HAART itself making it is difficult to derive
definitive conclusions about whether ARV therapy affects the
incidence of lung cancer. To assess the impact of ARV
therapy directly, smaller studies have compared those treated
with HAART with those who were not and found conflicting
evidence regarding whether HAART lowered the risk of lung
cancer10,57 or increased it.58,59 The larger ASD/HOPS data-
base analysis concluded that the incidence of lung cancer did
significantly decrease with ARV therapy use.9 Nevertheless,
a French analysis of the large FHDH-ANRS CO4 (French
Hospital Database on HIV) prospective cohort did not find a
correlation between exposure or duration of antiretroviral
therapy (ART) and lung cancer, although CD4 count at
cancer diagnosis seemed to be related.27 The international
SMART trial specifically evaluated the use of intermittent
ARV therapy for CD4 count 250 or until count 350
versus continuous ARV therapy to maintain viral suppres-
sion.60 The results indicated a threefold increased risk of lung
cancer in the intermittent arm compared with the continuous
ARV therapy arm. Nevertheless, this difference was not
significant, and numbers of events were small (n 8). Hence,
it seems that the use of ART alone may not be as important
as the target CD4 count.
RISK FACTORS
Behavioral Factors (Smoking and Intravenous
Drug Use)
As expected, cigarette smoking is an independent risk
factor for the development of lung cancer in HIV-positive
individuals.27,61 It is estimated that 51% of patients with HIV
have smoked cigarettes.62,63 The propensity of HIV-infected
patients to develop lung cancer is often attributed to the fact
that smoking is 2 to 3 times more common than in the general
population with rates reported as high as 85 to 100% in larger
series.25,26,37,42,46,59,64,65 This was reinforced by a report in
which none of the 865 nonsmoking HIV-positive individuals
developed lung cancer.10 Furthermore, among those who died
of respiratory cancer, up to 96% were smokers, which
strongly correlated with patient mortality.14,59
Parker et al.39 estimated that smoking alone could not
account for the increased risk of lung cancer. For example, a
20 to 35 pack-year smoking history has been associated with
lung cancer in patients with HIV, which by comparison is
often significantly less or at least equivalent to control sub-
jects in case series.25,41–43,46 One study illustrated that despite
adjusting for smoking, the risk for lung cancer remained
elevated with a SIR of 2.5 (95% CI: 1.6–3.5) and did not
normalize even when assuming all patients with HIV were
smokers or by doubling the smoking rate (SIR 1.7 and 2.4,
respectively).37 Although previous reports were limited by
incomplete smoking histories, Kirk et al.59 showed that indi-
viduals matched for age, sex, and smoking were still 3.6
times more likely to die of lung cancer in HIV-infected than
noninfected people. Examination of 3707 HIV-positive vet-
erans verified that irrespective of smoking, the risk of lung
cancer was almost double that of the 9890 HIV-negative
matched controls.66 Nevertheless, in a multivariate analysis,
smoking was associated with a much greater risk than HIV
alone (relative risk of 9.8 [95% CI: 4.44–21.4] versus 1.8
[95% CI: 1.28–2.15]).
In addition to smoking itself, several reports have
indicated that intravenous drug users are at a higher risk
for developing lung cancer.10,25,30,32,44,67 Nevertheless, this
is not consistent across studies, and the results may be
confounded by high rates of smoking among intravenous
drug users.10,32,37,59,64
Role of Immunodeficiency
Evaluation of the risk of lung cancer in transplant
recipients has further shifted the emphasis from lifestyle-
related risk factors to immunosuppression itself. Although
behavioral risk factors differ between patients with HIV/
AIDS and transplant patients, a large meta-analysis of 12
studies revealed that the higher risk for lung cancer was
comparable between patients with HIV/AIDS (SIR of 2.7
[95% CI: 1.91–3.87]) and organ transplant recipients that
received immunosuppressive therapy (SIR of 2.18 [95% CI:
1.85–2.57]).68 Additionally, a large meta-analysis has shown
that the risk of lung cancer is higher in patients who devel-
oped AIDS,33 whereas several other studies have demon-
strated a temporal association with the onset of
AIDS.31,32,34,36,44,67 The largest study to evaluate this associ-
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ation examined 1489 lung cancer cases among 397,927
patients with AIDS from 1980 to 2002 and showed a
markedly elevated SIR of 10.5 at the time of AIDS onset
(6 months before 3 months after) and a significant upward
trend in SIRs during the other periods from 60 months
(SIR of 1) before 60 months after (SIR of 2.9) AIDS
diagnosis.54 Nevertheless, it is also plausible that that the
higher incidence of lung cancer might be secondary to
closer surveillance of patients with AIDS.
Unlike ADCs, the risk for lung cancer does not seem to
be directly correlated to CD4 count.7,10,25,28,37,42,54,59,69,70 In
fact, the median CD4 count at diagnosis for NADCs is often
significantly higher than that reported with ADCs5,6,8,13,14,18
and for lung cancer, the CD4 count ranges from 121 to
364.25,26,28,42,46,48,70 Although CD4 count does not seem to
have a linear relationship with lung cancer incidence, Guiguet
et al.27 demonstrated that the rate of lung cancer doubled as
patient’s CD4 count decreased from 500 to 350–499 and
continued to increase as CD4 counts declined. This French
Hospital Database on HIV (FHDH-ANRS CO4) cohort also
demonstrated that a recent low CD4 count predicted cancer
risk irrespective of duration. Silverberg et al.71 examined
19,280 HIV-infected US Kaiser patients in the post-HAART
era and showed that lung cancer was only elevated in those
with CD4 counts 200. In addition to predicting risk, CD4
count may also be related to lung cancer severity as implied
by Brock et al.25 who noted a slight inverse correlation of
various CD4 count ranges to advanced stage cancer. These
studies reinforce the importance of immunosuppression as
indirectly measured by CD4 count.
Given that many factors result in the variability of CD4
counts, CD4 nadir is often used as a surrogate marker for
immunodeficiency. Several small reports have failed to dem-
onstrate a significant association between CD4 nadir and lung
cancer incidence, although one study did suggest a positive
trend.35,37 This association proved to be significant in the
larger ASD/HOPS database analysis9 but not predictive in the
FHDH-ANRS CO4 cohort. Therefore, it is clear that patients
with HIV/AIDS are at higher risk for developing lung cancer
and that immunosuppression itself is a risk factor, although
the exact role of immunodeficiency remains to be elucidated.
Potential Viral Oncogenesis
HIV itself has been implicated as a potential cause for
oncogenesis. Specifically, evidence suggests that the Tat
protein required for viral replication may also affect genes
involved in controlling cellular proliferation.72 Nevertheless,
studies have not discovered a link between HIV viral load and
lung cancer occurrence.37,59 An analysis of 92 patients with
HIV with lung cancer indicated that viral load may be linked
to lung cancer severity,25 but this was inconsistent with the
fact that 63% of HIV-infected patients who died of lung
cancer had RNA levels 500.14
Other viruses have been investigated in an attempt to
account for the elevated lung cancer risk in the setting of
moderate immunosuppression. Stebbing et al.73 found no
evidence of KS-associated herpes virus or any of the cancer-
associated human polyomaviruses in the tumor samples of
HIV-related lung cancer. On the other hand, human papillo-
mavirus (HPV) DNA has been found in about 25% of all lung
cancer cases with regional distributions higher in Asian
compared with western populations.74 HPV 16 and 18 E6
oncoproteins have also been linked to nonsmoking females
with adenocarcinoma histology.75,76 Nevertheless, studies
have failed to reveal a causal relationship between HPV and
lung cancer in general.
CLINICAL MANIFESTATIONS
Demographics
Lung cancer in HIV-positive individuals disproportion-
ately affects younger patients with a median age that range
from 38 to 49 years, significantly less than controls (46 versus
64 years) (Table 2).22,24,25,39,41,42,46,49,65,67,77 As expected with
most cancers, the risk of lung cancer increases with age.25,37
Thus, the post-HAART shift in age distribution toward mid-
dle aged patients with AIDS places this group at a higher risk
for lung cancer.55 Historically, men have the highest risk for
lung cancer, which likely reflected the male predominance
seen in the HIV population and among smokers.63 With
increasing prevalence of HIV, lung cancer that occurred
almost exclusively (90% of cases) in men is now being
diagnosed in women in up to a third of all cases.37,70,78
HIV-infected women are not only at increased risk for lung
cancer but also seem to have higher SIRs than male counter-
parts based on several studies.32,33,36,44,67 Nevertheless, a
recent study implies that women are at higher risk of devel-
oping lung cancer irrespective of HIV status.61 Similar to
gender, the proportion of African Americans infected with
HIV is on the rise, ultimately altering the demographics of the
at risk population in the United States.25,79
Clinical Presentation
Although the characterization of lung cancer in patients
with HIV is limited to small case series, two reports described
cough, weight loss, and dyspnea as the most common symp-
toms. Other symptoms typically observed were fever, night
sweats, chest pain, and anorexia.42,43 HIV-infected patients
were more likely to be symptomatic than controls and often
presented with tachypnea, cachexia, tachycardia, and fever.
No significant difference in blood counts were detected.43
Radiographically, patients presented with peripherally lo-
cated masses and infiltrates (29/41), often involving the upper
lobes (27/29 of peripheral tumors). Adenopathy occurred in
about half of patients, whereas effusions occurred in about
one third.43,65,80
The most common histologic diagnosis is adenocarci-
noma (34–67%) followed by squamous cell (17–39%), large
cell (3–16%), and bronchoalveolar (2–3%) cancer in HIV-
positive patients. Non-small cell lung cancer represents 67 to
86% of primary lung cancers in patients with HIV; small cell
lung cancer comprises another 6 to 14% with unidentified
subtypes accounting for the remaining percentage.22,24–26,37,54,65
The majority of patients present with either advanced stage III
(18–29%) or IV (50–68%) disease.25,26,54,65 Histology and stage
distribution in HIV-positive patients were comparable with non-
HIV controls in two studies26,42; however, a larger contemporary
study confirmed prior observations that a significantly higher
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percentage of patients with HIV presented with more advanced
stage lung cancer.25
TREATMENT AND PROGNOSIS
Data on lung cancer treatment in HIV-infected patients
are also largely limited to case descriptions. About one fourth
of patients with HIV did not receive lung cancer directed
therapy in a large US case series during the pre and HAART
era as opposed to 12% in a post-HAART French study.24,25 In
both instances, poor performance status was the primary
reason that patient’s were not treated. HIV-infected patients
are less likely to undergo curative surgery than noninfected
patients mainly due to advanced stage.25 Nevertheless, two
thirds of HIV-positive patients in three separate studies were
deemed ineligible for surgery based on poor performance
status or prior pulmonary infections.22,26,81 Massera et al.82
reported successful surgical resection with no major compli-
cations in two patients with CD4 200. The advent of
HAART did not seem to increase the percentage (13% versus
15%) of patients that were eligible for curative surgery.25
Those who were not surgical candidates were mainly treated
with radiation alone (39%) and to a lesser extent, chemother-
apy (10%) or combined modality treatments (13%). This
differed vastly from a French study in which all nonsurgical
patients received either chemotherapy (63%) or chemoradia-
tion (12%).24 Among the 74 patients with HIV treated in
various post-HAART studies, only three suffered from treat-
ment-related deaths, whereas the majority still died as a result
of their cancer.22,24,83 Opportunistic infections occurred in 8
of 25 patients treated with systemic chemotherapy, but this
likely represents the added complication of advanced immu-
nosuppression because the median CD4 count was 150.26 On
the other hand, despite presenting with a poor performance
status and approximately 50% developing grade 3 or 4
hematologic toxicities, HIV-infected patients received a sim-
ilar number of chemotherapy cycles with equivalent out-
comes to HIV-negative controls in the modern era.83 Addi-
tionally, none of the patients treated with systemic
chemotherapy in the post-HAART era died of an opportunis-
tic infection arguing against withholding treatment on the
basis of immunodeficiency alone.24,83 With the use of tho-
racic radiotherapy, esophagitis has been noted to be the most
common adverse event, similar to non-HIV patients.24,26 An
additional complicating factor in the treatment of patients
with HIV with lung cancer is the potential interaction of ART
with chemotherapy that has yet to be fully defined.84
Lung cancer represents 5% of all deaths and 15% of all
cancer deaths in the HIV population.14 Traditionally, patients
with lung cancer and HIV disease experience a shorter
median survival of only 3 to 9 months and have a poor overall
prognosis.8,25,26,41,43,46,85 In a study by Sridhar et al.,42 the
median survival was 3 months for HIV-infected patients with
lung cancer, compared with 10 months in a matched non-HIV
control group. Notably, none of the patients in the HIV cohort
survived beyond 1 year. Mortality in this population has been
associated with African American race and advanced stage at
lung cancer diagnosis, which did not differ by HIV status in
a multivariate analysis.25 Favorable prognostic factors in-
clude early-stage disease, good performance status, and the
use of HAART.24 Survival by stage seems to be equivalent to
non-HIV patients implying that patient with HIV mortality
TABLE 2. Patient Characteristics
Sridhar
et al.42
Vyzula
et al.46
Tirelli
et al.26
Alshafie
et al.23
Spano
et al.48
Brock
et al.25
Lavole
et al.24
Bertolaccini
et al.22
Patients (n) 19 16 36 11 22 92 49 26
Years 86–91 88–95 86–98 90–94 93–02 86–04 96–07 03–07
Median age (yr) 47 45 38 50 45 46 46 39
Males (%) 100 94 89 82 86 67 86 85
Race, W/B (%) 63/21 — — 0/91 — 21/79 94/— —
Smoking (%) 94 100 94 90 95 99 100 85
Median pack-years 60 30 40 40 30 31 30
IVDU (%) 21 63 69 81 23 58 17 58
Homosexual (%) 32 38 17 0 45 — 18 23
Adenocarcinoma (%) 42 50 36 46 36 48 67 —
Squamous cell (%) 31 19 33 36 50 17 17 —
Large cell (%) 11 19 14 9 5 5 17 —
Small cell (%) 5 12 14 0 5 9 — 19
Other (%) 11 — 3 9 5 21 — —
Median CD4 121 184 150 329 364 305 350 143
CD4 200 (%) 53 54 44 30 9 — — —
Latency (yr) 5.5 8.6 —
PS 2 (%) 37 69 43 — 69 — 71 —
Stage III/IV (%) 79 81 84 90 75 87 84 76
Median survival (mo) 3 5.4 5 3 7 6.3 8.1 23
IVDU, intravenous drug user; PS, performance status.
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maybe worse due to higher proportion of patients with ad-
vanced disease.25,83
More encouraging survival results were noted by Ber-
tolaccini et al.22 who demonstrated a median survival of 23
months in HIV-infected patients with lung cancer who re-
ceived anticancer therapy. The 4-year survival rate was 54%.
Nevertheless, larger comparable studies have indicated that
the overall survival still remains poor ranging from 6.3 to 8.1
months in the HAART era.24,25,48 Poorer mortality outcomes
may be in part related to patients not receiving appropriate
therapy, but this does not explain why mortality in surgically
treated patients with HIV was twice that of matched controls
when perioperative factors did not play a role.86
FUTURE DIRECTIONS
The landscape of HIV has changed dramatically since
the institution of HAART. As AIDS-related illnesses decline,
lung cancer has emerged as a significant cause of morbidity
and one of the leading causes of mortality. HIV-infected
patients are at least 2 to 3 times more likely to develop lung
cancer than the general population. Immunodeficiency espe-
cially CD4 counts 500 seems to place HIV-infected indi-
viduals at a higher risk, but the development of lung cancer
itself does not seem to be directly related to absolute CD4
count.27,87 Rather, CD4 count at cancer diagnosis with its
inherent variability seems to be a measure of the degree of
immunosuppression. Although the use of ART itself may not
clearly decrease the risk of lung cancer in this population, it
is already known that cancer risk and general mortality in
ARV therapy-treated individuals with CD4 counts 500
approaches that of the general population.88,89 Therefore, the
current available evidence supports the idea that targeting a
higher CD4 count with therapy may have some beneficial
effects in preventing lung cancer.
Smoking is clearly associated with the risk of lung
cancer and seems to have a greater impact within the HIV
population compared with the general population. Therefore,
strategies to decrease the smoking prevalence are of great
importance. In addition, persistent pulmonary complaints or
radiologic abnormalities in the chest should be aggressively
pursued. Lung cancer screening has not demonstrated a
mortality benefit in the general population, but studies are
ongoing, and data in patients with HIV are lacking. Although
screening CTs have not yet become the standard of care in
this high-risk smoking population, one must take note that
60% of HIV-positive patients had chest x-rays that were
negative for malignancy within a year of diagnosis.25,90
Patients with HIV with lung cancer seem to have a
more aggressive presentation and a poorer prognosis com-
pared with the general population. This may be in part due to
a reluctance or inability to treat patients who are chronically
ill and immunosuppressed. Nevertheless, it seems that pa-
tients who are treated do benefit from improved outcomes
with tolerable side effects. Although these studies are often
small case reports that introduce an underlying bias. There is
limited evidence to guide lung cancer therapy for these
patients, and more prospective studies are needed. Further
characterization of the disease may help guide targeted ther-
apies that can potentially treat patients with fewer toxicities.
Future studies should focus on understanding the prevalence
of molecular abnormalities such as epidermal growth factor
receptor mutation, Kirsten rat sarcoma mutation, and echino-
derm microtubule-associated protein-like 4-anaplastic lym-
phoma kinase translocation. This might lead to the develop-
ment of tailored therapeutic options for patients with HIV
with lung cancer.
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